## **SAFETY DATA SHEETS**

# This SDS packet was issued with item:

078938281

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078927125 078933320 078933322



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

### **SAFETY DATA SHEET**

09/27/2021

Section 1: Identificat	ion			
Product information				
Product Name	Famciclovir Tablets, 125 mg, 250 mg and 500 mg			
Active substance	Famciclovir			
Intended Uses	Famciclovir Tablets is indicated for the treatment of recurrent herpes labialis.			
Company Details				
Manufacturer	Hetero labs limited, Unit V, Polepally, Jadcherla Mahaboob Nagar-509 301, India.			
Distributor	Camber Pharmaceutica	als, Inc, Piscatway, NJ 08854		
Section 2: Hazard(s)	Identification			
Precautionary	Obtain special instructions before use.			
Statements	Do not handle until all safety precautions have been read and understood.			
	Wash thoroughly after handling.			
	Avoid contact during pregnancy/while nursing.			
	Avoid release to the environment.			
	Collect spillage.			
Effects of	The potential for exposure is reduced in finished pharmaceutical form.			
Overexposure	Overexposure by inges	tion may cause increased severity of adverse effects.		
	Individuals with underly	ring renal disease may be at risk for acute renal failure.		
Hazard Statements	May be harmful if swallowed.			
Potential Health	Inhalation: Not expected to be an inhalation hazard in final pharmaceutical form.			
hazards	Eye Contact: Not expected to be a hazard to the eye in final pharmaceutical			
	form.			
	Skin Contact: Not expected to be a hazard to the skin. Can cause hypersensitive			
	reactions resulting in rash, redness, itching and inflammation.			
	Ingestion: May be harmful if ingested. Ingestion may cause headache, nausea,			
	diarrhea and abdominal discomfort.			
_	on/Information on Ingr			
Components		CAS No.		
Famcyclovir		104227-87-4		
Lactose Monohydrate		63-42-3		
Sodium starch Glycolate		9063-38-1		
Hydroxypropyl Cellulose		9004-64-2		
Magnesium Stearate		557-04-0		
Opadry White, IHS (YS -1 -7003)		117698-04-1		



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

sures		
Check the vital functions-Unconscious: maintain adequate airway and		
respiration. Flush with water while holding eyelids open for at least 1		
minutes. Seek medical attention immediately. Allow the victim to rest in a we		
ventilated area. Seek immediate Medical attention.		
Should not pose a hazard in the final form. If breathing is difficult, move to		
fresh air. Get medical attention immediately.		
Rinse immediately with plenty of water for at least 15 minutes. Keep eye wid		
open while rinsing. If exposed or concerned: Get medical attention/advice.		
Take off contaminated clothing and shoes immediately. Wash off immediately		
with plenty of water for at least 15 minutes. Discard contaminated clothing or		
wash before re-use. If exposed or concerned: Get medical attention/advice.		
If swallowed, wash out mouth with water, provided Person is conscious. Seek		
medical advice. Never give anything by mouth to an unconscious person.		
Wash out mouth with water. Do not induce vomiting unless directed by		
medical personnel. Seek medical attention immediately. Rinse mouth with		
water-Immediately after ingestion: give lots of water to drink		
Measures		
Not available		
Use water spray, dry chemical, carbon dioxide or material appropriate for fire		
in surrounding area		
Wear full protective clothing and self-contained breathing apparatus.		
Carbon dioxide, carbon monoxide, oxides of nitrogen		
Carbon dioxide, carbon monoxide, oxides of nitrogen		
Carbon dioxide, carbon monoxide, oxides of nitrogen		
Decontaminate protective clothing and equipment before reuse.		
Decontaminate protective clothing and equipment before reuse.		
Decontaminate protective clothing and equipment before reuse.		
Decontaminate protective clothing and equipment before reuse.  lease Measures  Wear protective clothing and equipment consistent with the degree of hazard.		
Decontaminate protective clothing and equipment before reuse.  lease Measures  Wear protective clothing and equipment consistent with the degree of		
Decontaminate protective clothing and equipment before reuse.  lease Measures  Wear protective clothing and equipment consistent with the degree of hazard.		
Decontaminate protective clothing and equipment before reuse.  lease Measures  Wear protective clothing and equipment consistent with the degree of hazard.  For large spills, take precautions to prevent entry into waterways sewers, or		



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Section 7: Handling and	Storage	
Handling Precautions	Avoid exposure and formation of dust and aerosols. When handling broken or	
	crushed tablets or capsules, ensure worker exposure is below the	
	recommended exposure limit. Keep away from heat and sources of ignition.	
	Prevent release to drains and waterways.	
Container	Store in the original primary packaging as provided.	
Requirements		
Storage Conditions	Store at 20° to 25° C (68° to 77°F) [see USP Controlled Room Temperature].	
Section 8: Exposure Co	ntrols/Personal Protection	
Exposure Limits	None	
Engineering Controls	Not required when handling tablets or containers. Ventilation should be	
	matched to conditions.	
Respiratory	Not required when handling tablets or containers. NIOSH/MSHA approved	
Protection	respirators for protection should be used if respirators are found to be	
	necessary. Ventilation should be matched to conditions.	
Personal Protection	Not required when handling tablets. If containers are compromised or	
	exposure is likely wear: Goggles, Lab Coat, Gloves	
Recommended	Eye wash, washing facilities	
Facilities		
Section 9: Physical and	Chemical Properties	
General Information		
Appearance		
Physical State	Solid	
Form	Tablet	
Odour	Not available	
рH	Not available	



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

# Description & Availability

 125 mg: Off white, round, biconvex, film coated tablets, debossed with 'l' on one side and '50' on the other side. They are available as follows

Bottles of 30 tablets NDC 31722-706-30
Bottles of 60 tablets NDC 31722-706-60
Bottles of 100 tablets NDC 31722-706-01
Bottles of 500 tablets NDC 31722-706-05
Bottles of 1000 tablets NDC 31722-706-10

 250 mg: Off white, round, biconvex, film coated tablets, debossed with 'l' on one side and '49' on the other side. They are available as follows

 Bottles of 30 tablets
 NDC 31722-707-30

 Bottles of 60 tablets
 NDC 31722-707-60

 Bottles of 100 tablets
 NDC 31722-707-01

 Bottles of 500 tablets
 NDC 31722-707-05

 Bottles of 1000 tablets
 NDC 31722-707-10

• 500 mg: Off white, oval, film coated, biconvex tablets, debossed with 'l' on one side and '48' on the other side. They are available as follows

Bottles of 30 tablets NDC 31722-708-30
Bottles of 60 tablets NDC 31722-708-60
Bottles of 100 tablets NDC 31722-708-01
Bottles of 500 tablets NDC 31722-708-05
Bottles of 1000 tablets NDC 31722-708-10

### **Section 10: Stability and Reactivity**

Stable under recommended storage conditions

Section 11: Toxicological Information

### Carcinogenesis, Mutagenesis, Impairment of Fertility

### Carcinogenesis

Two-year dietary carcinogenicity studies with famciclovir were conducted in rats and mice. An increase in the incidence of mammary adenocarcinoma (a common tumor in animals of this strain) was seen in female rats receiving the high dose of 600 mg/kg/day (1.1 to 4.5x the human systemic exposure at the recommended total daily oral dose ranging between 2000 mg and 500 mg, based on area under the plasma concentration curve comparisons [24 hr AUC] for penciclovir). No increases in tumor incidence were reported in male rats treated at doses up to 240 mg/kg/day (0.7 to 2.7x the human AUC), or in male and female mice at doses up to 600 mg/kg/day (0.3 to 1.2x the human AUC).



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

### Mutagenesis

Famciclovir and penciclovir (the active metabolite of famciclovir) were tested for genotoxic potential in a battery of in vitro and in vivo assays. Famciclovir and penciclovir were negative in in vitro tests for gene mutations in bacteria (S. typhimurium and E. coli) and unscheduled DNA synthesis in mammalian HeLa 83 cells (at doses up to 10,000 and 5,000 mcg/plate, respectively). Famciclovir was also negative in the L5178Y mouse lymphoma assay (5000 mcg/mL), the in vivo mouse micronucleus test (4800 mg/kg), and rat dominant lethal study (5000 mg/kg). Famciclovir induced increases in polyploidy in human lymphocytes in vitro in the absence of chromosomal damage (1200 mcg/mL). Penciclovir was positive in the L5178Y mouse lymphoma assay for gene mutation/chromosomal aberrations, with and without metabolic activation (1000 mcg/mL). In human lymphocytes, penciclovir caused chromosomal aberrations in the absence of metabolic activation (250 mcg/mL). Penciclovir caused an increased incidence of micronuclei in mouse bone marrow in vivo when administered intravenously at doses highly toxic to bone marrow (500 mg/kg), but not when administered orally.

### Impairment of Fertility

Impairment of fertility: Testicular toxicity was observed in rats, mice, and dogs following repeated administration of famciclovir or penciclovir. Testicular changes included atrophy of the seminiferous tubules, reduction in sperm count, and/or increased incidence of sperm with abnormal morphology or reduced motility. The degree of toxicity to male reproduction was related to dose and duration of exposure. In male rats, decreased fertility was observed after 10 weeks of dosing at 500 mg/kg/day (1.4 to 5.7x the human AUC). The no observable effect level for sperm and testicular toxicity in rats following chronic administration (26 weeks) was 50 mg/kg/day (0.15 to 0.6x the human systemic exposure based on AUC comparisons). Testicular toxicity was observed following chronic administration to mice (104 weeks) and dogs (26 weeks) at doses of 600 mg/kg/day (0.3 to 1.2x the human AUC) and 150 mg/kg/day (1.3 to 5.1x the human AUC), respectively.

Famciclovir had no effect on general reproductive performance or fertility in female rats at doses up to 1000 mg/kg/day (2.7 to 10.8x the human AUC).

Two placebo-controlled studies in a total of 130 otherwise healthy men with a normal sperm profile over an 8 week baseline period and recurrent genital herpes receiving oral famciclovir (250 mg twice daily) (n=66) or placebo



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA. Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail:contact@heterodrugs.com URL:http//www.heterodrugs.com

(n=64) therapy for 18 weeks showed no evidence of significant effects on sperm count, motility or morphology during treatment or during an 8-week follow-up.

### **Animal Toxicology and/or Pharmacology**

Juvenile toxicity study in rats: In juvenile rats, famciclovir was administered daily at doses of 0, 40, 125, or 400 mg/kg/day for 10 weeks beginning on post-partum Day 4. There were no treatment related deaths or clinical observations. The toxicity of famciclovir was not enhanced in juvenile rats compared to that in the adult animals.

### **Section 12: Ecological Information**

No relevant studies identified.

### **Section 13: Disposal Considerations**

### Waste treatment methods

Additional information	Wash clothing and equipment after handling
------------------------	--

### Ecology - waste materials

Take up liquid spill into absorbent material-Scoop absorbed substance into closing containers.

### Section 14: Transport Information

### IATA/ICAO - Not Regulated

IATA Proper shipping Name N/A IATA UN/ID No N/A IATA Hazard Class N/A IATA Packaging Group N/A IATA Label N/A

### IMDG - Not Regulated

IMDG Proper shipping Name N/A IMDG UN/ID No N/A **IMDG Hazard Class** N/A IMDG Flash Point N/A **IMDG** Label N/A

### **DOT** - Not Regulated

**DOT Proper shipping Name** N/A DOT UN/ID No N/A



Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

DOT Hazard Class : N/A
DOT Flash Point : N/A

DOT Packing Group : N/A

DOT Label : N/A

### **Section 15: Regulatory Information**

This Section Contains Information relevant to compliance with other Federal and/or state laws.

### **Section 16: Other Information**

### Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero labs limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero labs limited reserves the right to revise this MSDS.